The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Other Relationship - AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Jazz Pharmaceuticals; Merck
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
 
Mehmet Nahit Sendur
No Relationships to Disclose
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chong Kun Dang Pharmaceutical; CJ Healthcare; Green Cross; Janssen; Lilly; Menarini; Merck; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda
Consulting or Advisory Role - ST Cube
Travel, Accommodations, Expenses - Blueprint Medicines; Takeda
 
Irfan Cicin
Consulting or Advisory Role - Abbvie (Inst); Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Nobelpharma (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Teva
Speakers' Bureau - Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Perran Fulden Yumuk
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Takeda (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Nestle health science (I); Novo Nordisk (I); Roche (Inst)
Research Funding - Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Francisco J Orlandi
Honoraria - Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - AstraZeneca/MedImmune; Roche
Research Funding - Amgen; Astellas Medivation; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celltrion; Genentech/Roche; mAbxience; MSD Oncology; Nektar; Pfizer; Sanofi
Travel, Accommodations, Expenses - Genentech/Roche; MSD Oncology
 
Ticiana A. Leal
No Relationships to Disclose
 
Olivier Molinier
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Nopadol Soparattanapaisarn
No Relationships to Disclose
 
Adrian Langleben
No Relationships to Disclose
 
Raffaele Califano
Stock and Other Ownership Interests - The Christie Private Care
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Lilly; MSD; Roche; Takeda
 
Balazs Medgyasszay
No Relationships to Disclose
 
Te-Chun Hsia
No Relationships to Disclose
 
Gregory Alan Otterson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Guardant Health; Novocure
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst)
 
Lu Xu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Thomas A. Burke
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ayman Samkari
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Michael J. Boyer
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck Sharp & Dohme